glp-1 when to take How long should you drugs? Study links longer use lower heart risk Your guide to GLP-1 side

In 2025, the company delivered a solid +8.56% YoY revenue growth, driven by its immunology portfolio: Skyrizi ($17.56B) continues to surge with strong uptake across psoriasis and IBD, Rinvoq ($8.3B) is expanding rapidly across multiple inflammatory conditions, while Humira ($4.54B) continues to decline following loss of exclusivity marking a clear shift toward newer growth assets

Why this Matters: the Rise of GLP-1 Therapy Obesity is a rapidly growing public health issue in Canada and a major driver of emergency department presentations

As well as favorable reimbursement policies with government support for diabetes and obesity treatments, are a boost in access to cost-effective medications

Missing three or more doses effectively resets your body tolerance

haha Bryce Platt, PharmD Behavior follows the commercials

Food and Drug Administration: FDAs Concerns With Unapproved GLP-1 Drugs Used for Weight Loss GLP-1 Agonists